Recent research has shown that defined sets of exogenous factors are sufficient to convert rodent and human somatic cells directly into induced neural stem cells or ne ural precursor cells (i NSCs/iNPCs). The process of transdifferentiation bypasses the step of a pluripotent state and reduces the risk of tumorigenesis and genetic instability while retaining the self-renewing capacity. Th is iNSC/iNPC technology has fueled much excitement in regenerative medicine, as these cells can be differentiated into target cells for re placement therapy for neurodegenerative diseases. Patients' somatic cell-derived iNSCs/iNPCs have also been proposed to serve as dis ease models with potential value in both fun damental studies and clinical applications. This review focuses on the mechanisms, tec hniques, and app lications of iNSCs/iNPCs from a series of related studies, as well as further efforts in designing novel strategies using iNSC/iNPC technology and its potential applications in neurodegenerative diseases.
Introduction
Neurodegenerative disease is a condition in which neurons in the brain and spinal cord are gradually and progressively lost, leading to nervous system dysfunction.
As the proportion of elderly individuals in the total population is rising, there is an increase in the number of patients afflicted with neurodegenerative diseases. Recently, a series of experimental studies has shown that somatic cells can be directly converted into iNSCs/ iNPCs by different combinations of exogenous factors [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] .
Compared to induced neurons, iNSCs/iNPCs have the advantage of self-renewal and differentiation. These dividing cells may have considerable clinical applications, being able to generate suffi cient amounts of cells.
A patient's somatic cell-derived iNSCs/iNPCs can avoid the ethical issues raised by embryonic stem cells, and have a lower risk of tumorigenesis and genetic instability compared to induced pluripotent stem cells (iPSCs). Besides ce ll replacement therapy [4] , they can Neurosci Bull October 1, 2015, 31(5): 589-600 590 also be used to establish disease models [12] for studying pathogenesis, screening drugs, and monitoring efficacy.
But this technology is still in the preliminary stage, and many problems need to be solved before clinical use.
Here we review the techniques, mechanisms, and applications of iNSCs/iNPCs in neurodegenerative diseases, and discuss the limitations and prospects for development.
Me chanisms of Di rect Conversion from Somatic Cells into i NSCs/iNPCs
It has been confi rmed that adult somatic cells retain broad cellular plasticity, so that they can directly change fate process of transdifferentiation [13] . Accurate coordination between transcription factors, as well as the epigenetic modifications of target genes, are the key determinants of transdifferentiation. Wernig and colleagues revealed that a precise match between pioneer factors and the chromatin context at key target genes determines transdifferentiation [14] .
Basic Function of Transcription Factors
The process of transcription defines the specific pheno Kim and co lleagues showed that the induction of four reprogramming factors (Oct4, So x2, Klf4, and c-myc) can effi ciently convert fi broblasts into functional iNSCs/iNPCs [1] .
Lujan and colleagues infected mouse embryonic fi broblasts derived from Sox2-EGFP mice with a set of 11 transcription factors highly expressed in NPCs, and successfully obtained colonies that expressed NPC-specifi c genes and differentiated into neurons and astrocytes. Using stepwise elimination, they also found that two different combinations of transcription factors (So x2/FoxG1; Sox2/FoxG1/Brn2) are capable of generating clonal self-renewing iNPCs [2] .
According to the iPSC technology and the results of screening for transcription factors with high expression in NSCs/NPCs, the transcription factors noted above play different roles in direct transdifferentiation.
Th e Sox2 gene belongs to the Sry gene family, and it is widely expressed among cells within the neural tube at early stages of neurodevelopment. Its expression is subsequently localized to the ventricular layer in the cortex, where NSCs/NPCs are present after the midfetal period [15] . These fi ndings indicate that the Sox2 gene may be a key factor with high expression in NSCs and
NPCs. Sox2 functions to maintain the pluripotent state and self-renewal ability of iNSCs/iNPCs, and to inhibit the differentiation process [2, 6, 16] [15] . Therefore, Sox2
functions by acting as a molecular switch in several major signaling pathways.
Th e Oct4 gene is a member of the POU transcription with crucial roles in the early stages of differentiation [17] . Janghwan Kim's team pointed out that Oct4 is the only indispensable reprogramming factor of the four Oct4, Sox2, Klf4, and c-myc to obtain pluripotent stem cells [1] .
The functions of Oct4 depend on its ability to recognize and bind to DNA regulatory regions alone or in cooperation with other transcription factors (such as Sox2) and on its capacity to recruit other factors required to regulate the expression of specifi c sets of genes [17] .
Foxg1 is an important member of the Fox gene family, known to play a central role in cortical development in that it regulates progenitor proliferation, specification, and telencephalic patterning. It is also expressed dynamically during the post-mitotic multipolar phase to critically regulate the assembly and integration of pyramidal neuron precursors into the cortical network [18] .
Being upstream of many genes, Foxg1 may regulate the proliferation and differentiation of NSCs during the early phase of embryogenesis [19] . Brancaccio and colleagues demonstrated that the main function of Foxg1 in the cerebral cortex during the embryonic period is to maintain the normal status of the precursor cell bank and ensure the normal process of neuron proliferation, as well as regulating the fate of NPCs by suppressing the genesis of glial cells, while promoting differentiation to neurons [20] .
Fasano demonstrated that the cooperation of Bmi-1 and Foxg1 is required to maintain the pluripotency and selfrenewal capability of NSCs [21] .
C-myc, a member of the pro to-oncogene family, can accelerate the rate of cell proliferation and enhance the self-renewal capacity of NSCs [22] . Klf4 is also involved in the regulation of cell proliferation and differentiation, and also participates in maintaining the pluripotent state. 
Ep igenetic Mod ifi cations of Target Genes in Direct Transdifferentiation to iNSCs/iNPCs
Epigenetic alterations can modify the activation of certain genes, without changing the DNA sequence. There are three major types of epigenetic mechanisms: DNA methylation, histone modification, and non-coding RNAmediated regulation [23] . The process of direct conversion from somatic cells to iNSCs/iNPCs also refers to these epigenetic modifi cations.
DNA met hylation DNA methylation is a key element in the hierarchy of control mechanisms that govern gene function and differentiation.
Cortese and colleagues dem onstrated significant enrichment of genes involved in neuronal differentiation, such as Jag1 and Tcf4, in a genome-wide screen for differential DNA methylation, providing robust evidence for the relevance of DNA methylation in early neuronal development [24] . Methyl-CpG-binding domain protein 1 (MBD1)
facilitates neuronal differentiation by direct binding to the promoter of FGF-2. MBD1-induced methylation of the FGF-2 promoter results in down-regulation of FGF-2 expression to undergo neuronal differentiation [25] . At the same time,
de novo DNA methylation and hypo-methylation are likely to be important for the process of transdifferentiation and maintenance of the pluripotent state [26] .
Zhang's group treated NIH/ 3T3 fibroblasts with a combination of 5-aza-dc, a DNA methylation inhibitor and
Tri chostatin A, a histone deacetylation inhibitor. By culturing the cells in a neural environment supplemented with reti noic acid (RA), they generated neuron-like cells from fibroblasts, and found that the pluripotent markers Sox2, klf4, c-myc, and Oct4 were expressed in repr ogrammed NIH/3T3 fi broblasts and the total DNA methylation level was signifi cantly decreased after treatment, indicating a role of the demethylation process in inducing and maintaining the pluripotent state [27] . [28] . Burgold also reported that Jmjd3 controls the expression of key regulators and markers of neurogenesis and is required for commitment to the neural lineage [29] .
Hist one modification
Zuryn and colleagues reported that Jmjd3.1 and the H3K4 [13] . H3K27 methyltransferase prevents Wnt-signal-mediated β-catenin action on neuronal genes and results in blockade of neuronal differentiation [23] .
Acetylation is another important histone modifi cation, which has impact on transcriptional activation by disrupting the electrostatic interaction between histone and the DNA backbone and acting as a docking site for the recruitment of transcriptional co-activators [23] . Zhu and colleagues formulated a chemical cocktail containing NaB (a histone deacetylase inhibitor, HDAC i) that, combined with the ectopic expression of Oct4, converted adult human dermal fi broblasts into human iNSCs [30] . Similarly, another HDACi (Trichostatin A, TSA) combined with 5-aza-2-deoxycytidine (5-aza-dC) dedifferentiated NIH/3T3 fi broblasts into neuronlike cells with RA supplement [27] .
Polycomb-group proteins are a family of proteins that remodel chromatin such that epigenetic silencing of Hox genes takes place. The Bmi-1 polycomb ring fi nger protein promotes NSC self-renewal and maintains the pluripotency of NSCs through the cooperation of Bmi-1 and Foxg1 [21] .
MicroRNAs MicroRNAs (miRNAs) are non-coding RNAs that range in size from 17 to 25 nucleotides and function as important post-transcriptional gene regulators. They also play essential roles in neuronal development and function.
MiRNAs interact with gene regulatory motifs to regulate the balance between neural progenitor self-renewal and differentiation [31] .
Recently, a set of brain-enriched microRNAs such as miR-9 and miR-124 have been found to promote the conversion of the non-neuronal fate of fi broblasts towards neurons [32] . MiR-9 regulates neural progenitor proliferation and differentiation by targeting Foxg1, Tlx, and Gsh2, among others. The overexpression of miR-9 promotes NSC differentiation by down-regulating Tlx expression, forming a double negative feedback loop with Hes1 [33] and suppressing Gsh2 and Foxg1 expression to negatively control progenitor proliferation [34] . MiR-124 is another brainenriched miRNA. Both loss-of-function and overexpression studies have reported that miR-124 is a promoter of neuronal differentiation and an inhibitor of progenitor selfrenewal [33] . Reported main targets of miR-124 to establish neuronal programs include Sox9 and Jag1(a Notch ligand) [33] .
The induction of transdifferentiation from fibroblasts to functional neurons can be accomplished via the action of miR-124 [32] .
In general, while miR-124, miR-125b, miR-137, miR-9, and let-7 promote neuronal differentiation, other miRNAs such as miR-134 and miR-184 have been implicated in neural progenitor maintenance and proliferation [31] .
The molecular network regulating the prol iferation and differentiation of NSCs is complex. The links between transcription factor expression and epigenetic modifiers require further studies. Research on the regulatory pathways of proliferation and differentiation of NSCs may help fi nd effective target points for direct transdifferentiation.
Meanwhile, treatment with repr ogramming factors on NSCs induces neuronal differentiation to obtain the neuron subtype that is needed. The network of several main signaling molecules [15, 21, 25, [33] [34] [35] [36] [37] that may regulate the proliferation and differentiation of NSCs is shown in Figure 1 .
Methods of Direct Conversion to iNSCs/iNPCs
Independent groups have demonstrated that directly- including p21 (cyclin-dependent kinase inhibitor) and pten (tumor suppressor gene), which in turn regulate NSC proliferation [35] .
Tlx also activates the Wnt signaling pathway, promotes transcription of the Oct4 gene, and can be inhibited by action of the Sox2 transcription factor. Sox2 and Oct4 coordinate to promote expression of the Nanog, Utf1, and Fgf4 genes to regulate the mechanism that maintains the pluripotency of stem cells [15] . MiR-9 regulates neural progenitor proliferation and differentiation by targeting Foxg1, Tlx, and Gsh2, among others [34] , while miR-124 targets Sox9 and Jagged [32] . APC, adenomatous polyposis coli; transcription factors and effi ciently converted the fi broblasts into iNPCs [2] . Ding and colleagues also used lentiviral [4] .
GSK
In fact, multiple independent experiments have demonstrated the feasibility of direct transdifferentiation from somatic cells into iNSCs/iNPCs (Table 1) .
Non-viral Plasmid Transfection
It has been demonstrated that insertion of a transgene into target cells is not necessary during the transdifferentiation
process. Transient expression of transdifferentiation factors transfected by non-viral vectors is also capable of direct reprogramming. Compared to viral vector transfection, this
method has a lower risk of mutagenicity and tumorigenicity.
Xu and colleagues reported the successful generation of iNPCs from fetal pig fibroblasts using non-integrative episomal vectors expressing reprogramming factors (Oct4, Sox2, Klf4, Lin28, and L-myc) without going through a pluripotent state, and showed lower tumorigenicity [38] .
RNA or Protein Transfection
Another way to avoid changes in the target cell genome and pro-neural genes, and can give rise to neurons that exhibit typical neuronal morphologies and express multiple neuronal markers [39] . Yakubov and colleagues presented a method that used transfection of the synthesized RNA of four transcription factors (Oct4, Sox2, Klf4, and c-myc) to 
Epigenetic Modifications Using Small Molecule Compounds
Epigenetic modification is a key determinant to complete the process of transdifferentiation using epigenetic small molecules instead of transcription factors. These epigenetic molecules regulate the reprogramming process through DNA methylation and histone modification, which has been demonstrated to promote transformation efficiency combined with specific transcription factors in a series of transdifferentiation studies.
A recent study showed that infection of postnatal and adult human and monkey fibroblasts with Sendai virus containing the Yamanaka factors (Oct3/4, Sox2, Klf4, and c-Myc), cultured in a chemically-defi ned medium containing leukemia inhibitory factor, the transforming growth factor-β (TGF-β) inhibitor SB431542, and the glycogen synthase kinase-3β (GSK-3β) inhibitor CHIR99021, caused the generation of iNPCs [41] . Zhu and colleagues identified a small-molecule combination of A83-01 (a TGF-β inhibitor) and CHIR99021 that enabled reprogramming of Oct4/ Sox2-transduced human neonatal fi broblasts into colonies expressing the human NSC marker Pax6 [30] . They also found that a combination of lysophosphatidic acid (a phospholipid derivative), rolipram (a phosphodiesterase-4 inhibitor), and SP600125 (a c-Jun N-terminal kinase inhibitor) facilitated the reprogramming of adult human dermal fibroblasts transduced with Oct4 alone [30] . Cheng and colleagues reported that iNPCs can be generated from mouse embryonic fibroblasts using a chemical [42] .
Biochemical Agents
Some biochemical agents can also be used to induce direct transdifferentiation or enhance this process when combined with transcription factors, such as chemicals and cytokines.
The main categories of chemical inducers of transdifferentiation into iNSCs/iNPCs are antioxidants and calcium channel blockers. Cai and colleagues examined the most representative antioxidant, β-mercaptoethanol, and found that it induces adipose-derived stromal cells to rapidly and efficiently differentiate into neurons in vitro [43] .
At the same time, calcium channel blockers play a role in transdifferentiation. Besides, numerous traditional
Chinese medicines also appear to be inducers of the transdifferentiation process, such as Lycium barbarum polysaccharide [44] , Salvia miltiorrhiza [45] , and Rehmannia glutinosa polysaccharide [46] with antioxidation similar to β-mercaptoethanol, and Panax notoginseng saponins [47] , ligustrazine [48] , and salidrosides [49] , which belong to the reprogrammed cells to RA-containing medium [27] .
Applications of Somatic Cell-Derived iNSCs/iNPCs in N eurodegenerative Diseases
Current therapies for neurodegenerative diseases are restricted to controlling symptoms, and their long-term use is limited due to the inevitable side-effects. At present, there is no effective treatment to prevent or delay the clinical progression of these diseases.
The iNSCs/iNPCs derived from patients have potential value in both fundamental studies and clinical applications.
Application of iNSCs/iNPCs would be very useful in various fields, such as obtaining target cells for transplantation therapy, establishing disease models, and drug screening, as well as for monitoring curative effects.
Cell Transplantation Therapy
At present, therapies for neurodegenerative diseases mainly rely on drug treatment, but it is difficult for drugs to pass through the blood-brain barrier and target the location of neuronal loss, so the curative effects are limited.
As a novel approach to neurodegenerative diseases, cell transplantation therapy has proven effective in animal disease models [4, 50] . partial lesion rat model of PD [51] .
Multiple sclerosis M ultiple sclerosis is an inflammatory After the injection of iNSCs, chronic experimental allergic encephalomyelitis in mice is ameliorated [50] .
In addition, stem cell t ransplantation therapy has also made certain progress in animal models of other neurodegenerative diseases such as H untington's disease [12] and amyotrophic lateral sclerosis (ALS) [52] .
iNSCs/iNPCs possess features that could solve some of the main problems in stem cell therapy. But there is still a lack of experimental evidence demonstrating the effectiveness of i NSC/iNPC transplantation therapy for the above diseases.
The key to the success of iNSCs/iNPCs transplantation in the treatment of neurodegenerative diseases is how to promote the differentiation of iNSCs/iNPCs into the target neuronal subtypes needed. In the future, more research will be needed to confi rm its advantages. repair and regenerative medicine, and disease modeling, in addition to a powerful tool for personalized drug tests [53] . to personalized modeling of toxicity in ALS [52] .
N eurodegenerative Disease Models

Studies
We predict that, in future, it may be feasible to evaluate the pathophysiological mechanisms of neurodegenerative diseases using iNSC/iNPC models, while animal disease models cannot perfectly mimic the development and progression of certain diseases. vitro cell-based models such as embryonic stem cells [54] and iPSCs [55] 
Drug screening
Challenges in the Application of iNSC/iNPC
Te chnology
The direct conversion of somatic cells into iNSCs/iNPCs provides a more convenient, effi cient, and safer cell source for the clinical treatment of neurodegenerative diseases.
It is also a new tool to study the pathological mechanisms of neurodegenerative diseases. However, research of this method is still in the preliminary stage, and many problems need to be solved before its clinical application.
Reducing the Risk of Tumorigenesis
The oncogenes c-myc and Klf4 play important roles in controlling the stemness of NSCs, while their sustained expression might lead to a tumorigenic tendency in target cells. Several recent experiments have shown that c-myc and Klf4 are dispensable for the production of iN SCs/ iNPCs [2, [6] [7] [8] , although the reprogramming process is significantly delayed and less efficient in the absence of these oncogenes. The process of direct conversion of somatic cells into iNSCs by a single factor, Sox2, does not generate tumors [6] .
Risks of Vi ral Vectors
The viral vector is the most commonly used tool in t ransfection technology. But its clinical application is 
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In order to improve the safety of transdifferentiation technology, the viral vectors can be replaced with inducible expression vectors [56] to regulate transgene expression, non-integrating plasmid vectors [38] , small molecule compounds [27, 30, 41, 42] , mRNA [40] or protein [39] , to make the transfection system safer and more efficient for clinical trials.
Impurity of th e Transdifferentiation Product
The transdifferentiation product is not pure, but contains a mixture of pluripotent cells, cells with different degrees of differentiation [57] , and even untransformed cells. Those 
Diffi culty in Controlling the Di fferentiation Direction of iN SCs/iNPCs
iNSCs/iNPCs are capable of differentiating into three main neural lineages, neurons, astrocytes, and oligodendrocytes [1, 3, 4, 6] . However, it is diffi cult to regulate the differentiation process in the direction needed.
Neuronal restricted progenitors (NR Ps) are a type of transitional intermediate cells that lie between multipotent neural progenitors and terminally-differentiated neurons during neurogenesis [9] ; these may be an ideal source for transplantation, as they only differentiate into neurons, rather than glial cells and other cell types. Lai and colleagues provided evidence of the direct conversion of primary human fibroblasts into NRPs by three defined factors, Sox2, c-myc, and Brn2/Brn4. When injected into the subventricular zone, the human induced NRPs migrated widely and integrated into different encephalic regions, differentiated into various neuronal subtypes but not glial cells, and contributed to the repair of the brain [9] .
Their research provides a new source of cells for cellular replacement therapy of neurodegenerative diseases.
Conclusions
The generation of iNSCs/iNPCs provides a unique 
